Thiefes A, et al. (2006) The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway. EMBO Rep 7, 838-44 16845370

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T183-p - JNK1 (human) ▲

Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase

Y185-p - JNK1 (human) ▲

Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase

S536-p - NFkB-p65 (human) ▲

Modsite: sGDEDFSsIADMDFS SwissProt Entrez-Gene Orthologous residues NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase

T180-p - P38A (human) ▲

Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene Orthologous residues P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase

Y182-p - P38A (human) ▲

Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene Orthologous residues P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase

S438-p - TAB1 (human) ▲

Modsite: tPTLTNQsPTLtLQS SwissProt Entrez-Gene Orthologous residues TAB1 (human): S438‑p, TAB1 iso2 (human): ‑, TAB1 (mouse): S436‑p, TAB1 (rat): S436‑p Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, mutation of modification site Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes yopJ (bacteria) decrease IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase SB203580 IL-1a inhibit treatment-induced increase

T187-p - TAK1 (human) ▲

Modsite: CDIQtHMtNNKGsAA SwissProt Entrez-Gene Orthologous residues TAK1 (human): T187‑p, TAK1 iso2 (human): T187‑p, TAK1 (mouse): T187‑p, TAK1 iso3 (mouse): T187‑p, TAK1 (rat): T187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) [IL-1RA (human)] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE TAK1 (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-1a increase IL-1a yopJ (bacteria) inhibit treatment-induced increase SB203580 IL-1a augment treatment-induced increase